{"id":2054,"date":"2017-07-24T14:53:27","date_gmt":"2017-07-24T12:53:27","guid":{"rendered":"http:\/\/lbti.ibcp.fr\/?page_id=2054"},"modified":"2026-05-07T08:51:09","modified_gmt":"2026-05-07T06:51:09","slug":"introduction-rocke","status":"publish","type":"page","link":"https:\/\/lbti.ibcp.fr\/?page_id=2054","title":{"rendered":"Rockefeller pole"},"content":{"rendered":"<p>The Rockefeller Centre, headed by Prof. <a href=\"mailto:fabrice.pirot@univ-lyon1.fr\">Fabrice Pirot<\/a> (Laboratory of Industrial Galenic Pharmacy), is located at the Faculty of Pharmacy in Lyon, 8 Avenue Rockefeller; F-69373 Lyon Cedex 08.<\/p>\n<p>The Rockefeller Division possesses expertise in both conventional and innovative formulation processes and in the design of drug-device combination products. Furthermore, the Rockefeller Division develops strategies for (i) the formulation and (ii) the evaluation of the efficacy of formulations intended for the treatment of epithelial, connective tissue and inflammatory conditions.<\/p>\n<p>More specifically, the Rockefeller unit is developing formulations (e.g. hydrogels) for (i) topical administration (i.e. treatment of atopic dermatitis, second-degree burns, skin infections and skin decontamination), (ii) enteral (e.g., microbiota transplantation) and (iii) intra-articular (e.g., treatment of rheumatoid arthritis). The efficacy and tolerability of the active ingredients and\/or formulations are tested under pathophysiological conditions on explants and primary cell cultures.<\/p>\n<p>Finally, the Rockefeller Centre contributes to the research activities of the university hospital platform for Pharmaceutical Manufacturing, Research and Innovation (<a href=\"http:\/\/www.fripharm.com\">FRIPHARM<\/a>) in the development of experimental drugs and innovative therapies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Rockefeller Centre, headed by Prof. Fabrice Pirot (Laboratory of Industrial Galenic Pharmacy), is located at the Faculty of Pharmacy in Lyon, 8 Avenue Rockefeller; F-69373 Lyon Cedex 08. The Rockefeller Division possesses expertise in both conventional and innovative formulation processes and in the design of drug-device combination products. Furthermore, the Rockefeller Division develops strategies<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-2054","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/lbti.ibcp.fr\/index.php?rest_route=\/wp\/v2\/pages\/2054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lbti.ibcp.fr\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/lbti.ibcp.fr\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/lbti.ibcp.fr\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lbti.ibcp.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2054"}],"version-history":[{"count":6,"href":"https:\/\/lbti.ibcp.fr\/index.php?rest_route=\/wp\/v2\/pages\/2054\/revisions"}],"predecessor-version":[{"id":5986,"href":"https:\/\/lbti.ibcp.fr\/index.php?rest_route=\/wp\/v2\/pages\/2054\/revisions\/5986"}],"wp:attachment":[{"href":"https:\/\/lbti.ibcp.fr\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}